Fas peptide mimetics and uses thereof
    32.
    发明授权
    Fas peptide mimetics and uses thereof 有权
    Fas肽模拟物及其用途

    公开(公告)号:US08680047B2

    公开(公告)日:2014-03-25

    申请号:US13210117

    申请日:2011-08-15

    CPC classification number: C07K14/70578 A61K38/00

    Abstract: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.

    Abstract translation: 开发了禁用Fas的外来肽模拟物。 构建了Fas受体 - 配体复合物的三维模型,并且结构上预测与结合配体相关的受体区域用于产生约束肽模拟物。 鉴定了外环抗Fas肽模拟物阻断Fas受体 - 配体相互作用,并在体外和体内调节Fas生物活性。 模拟物可用于例如治疗Fas相关病理学。

    METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR
    35.
    发明申请
    METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR 有权
    使用SURVIVIN抑制剂治疗癌症的方法

    公开(公告)号:US20120122910A1

    公开(公告)日:2012-05-17

    申请号:US13142731

    申请日:2010-01-19

    CPC classification number: A61K31/404 A61K31/352 A61K31/4704

    Abstract: Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells, comprising G2/M stage arrest, in a patient by administering a compound of formula (I), (II), (III), or (IV) are also disclosed. Further disclosed herein are methods of inducing apoptosis in cancer cells in a patient by administering a compound of formula (I), (II), (III), or (IV).

    Abstract translation: 本文公开了通过向患者施用存活蛋白的小分子抑制剂来治疗癌症的方法。 本文还公开了通过施用式(I),(II),(III)或(IV)的化合物来抑制患者存活蛋白二聚化的方法。 还公开了通过施用式(I),(II),(III)或(IV)的化合物在患者体内诱导细胞周期停滞的方法,包括G2 / M期骤停。 本文进一步公开的是通过施用式(I),(II),(III)或(IV)化合物来诱导患者癌细胞凋亡的方法。

    COMPOUNDS THAT BIND TO P185 AND METHODS OF USING THE SAME
    37.
    发明申请
    COMPOUNDS THAT BIND TO P185 AND METHODS OF USING THE SAME 有权
    与P185相结合的化合物及其使用方法

    公开(公告)号:US20100311669A1

    公开(公告)日:2010-12-09

    申请号:US12758435

    申请日:2010-04-12

    CPC classification number: C07K16/32 A61K2039/505 C07K2317/565

    Abstract: Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed.

    Abstract translation: 公开了包含其的新型肽和药物组合物。 与可检测的试剂和/或细胞毒性剂连接的共轭组合物肽。 被披露。 公开了检测肿瘤细胞表面上具有p185的肿瘤的方法。 公开了防止正常细胞转化成具有在其表面具有p185的肿瘤细胞的肿瘤的风险中的个体的肿瘤细胞的方法。 公开了在细胞表面处理具有p185的肿瘤细胞特征的癌症的个体的方法。

    Prevention of tumors with monoclonal antibodies against neu
    40.
    发明申请
    Prevention of tumors with monoclonal antibodies against neu 审中-公开
    使用针对neu的单克隆抗体预防肿瘤

    公开(公告)号:US20090104191A1

    公开(公告)日:2009-04-23

    申请号:US12316299

    申请日:2008-12-10

    CPC classification number: C07K16/32 A61K38/00 A61K2039/505

    Abstract: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed.

    Abstract translation: 公开了防止正常细胞向其表面具有p185的肿瘤细胞转化的方法。 所述方法包括施用特异性结合p185的抗体。 公开了防止正常细胞转化成肿瘤细胞的方法,所述肿瘤细胞在具有高发展肿瘤风险的个体的表面上具有p185。

Patent Agency Ranking